US equities
|
MU
$1,088.00
▲+0.00%
NVDA
$237.47
▲+0.00%
SNDK
$1,692.42
▲+0.00%
INTC
$113.12
▲+0.00%
AMD
$645.86
▲+0.00%
SPCX
$167.60
▲+0.00%
PLTR
$194.12
▲+0.00%
SKHY
$178.25
▲+0.00%
MU
$1,088.00
▲+0.00%
NVDA
$237.47
▲+0.00%
SNDK
$1,692.42
▲+0.00%
INTC
$113.12
▲+0.00%
AMD
$645.86
▲+0.00%
SPCX
$167.60
▲+0.00%
PLTR
$194.12
▲+0.00%
SKHY
$178.25
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tevogen Inc. - Common Stock
(NQ:
TVGN
)
6.490
UNCHANGED
Delayed Quote
Updated: 2:22 PM EDT, Oct 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tevogen Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
August 13, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
August 11, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion
August 11, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Unusual volume stocks in Monday's session
↗
August 11, 2025
Let's have a look at what is happening on the US markets on Monday. Below you can find the stocks with an unusual volume in today's session.
Via
Chartmill
Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow
August 11, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
August 11, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
August 08, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
August 07, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions
August 06, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology
August 05, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders
August 01, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion
August 01, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision
July 30, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare
July 28, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides
July 18, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility
July 17, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch
July 16, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs
July 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen’s New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation
July 10, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters
June 30, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery
June 18, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives
June 09, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships
May 30, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow
May 23, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting
May 22, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
May 12, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest
May 02, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment
April 30, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts
April 29, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
April 29, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
